Literature DB >> 32240907

Implementing an online radiotherapy quality assurance programme with supporting continuous medical education - report from the EMBRACE-II evaluation of cervix cancer IMRT contouring.

Simon L Duke1, Li-Tee Tan2, Nina B K Jensen3, Tamara Rumpold4, Astrid A C De Leeuw5, Christian Kirisits4, Jacob C Lindegaard3, Kari Tanderup3, Richard C Pötter4, Remi A Nout6, Ina M Jürgenliemk-Schulz5.   

Abstract

BACKGROUND AND
PURPOSE: EMBRACE-II is an international prospective study of IMRT and MRI-guided adaptive brachytherapy (IGABT) in locally advanced cervix cancer. An online radiotherapy quality assurance (RTQA) programme with minimal data transfer and supporting continuing medical education (CME) was implemented for IMRT contouring.
MATERIALS AND METHODS: Participant contours for six volumes-of-interest (VOIs) on one benchmark case were scored (2 = excellent, 1 = fair, 0 = revision required) against a consensus reference contour. For contours receiving a 0 or 1 score, additional qualitative comments were provided. The Jaccard conformity index (JCI) was retrospectively calculated. User interaction with CME content (pre-accreditation questionnaire, contouring atlas, practice cases, quizzes, internal target volume (ITV-T) guide) was analysed.
RESULTS: 78 clinicians submitted contours for evaluation. 41% passed at the first attempt, 44% after one revision and 6% after two or more revisions. 9% did not re-submit after failing. The lowest mean scores were for the elective nodal CTV (CTV-E) (1.01/2) and ITV-T (1.06/2). 60 different errors across the six VOIs were identified; five potentially had high impact on loco-regional control. A JCI cut-off of 0.7 would have identified 87% contours that failed expert assessment, but also excluded 54% of passing contours. 39 clinicians responded to the pre-accreditation questionnaire - 36% anticipated difficulties with the ITV-T and 13% with the CTV-E. 35% clinicians contoured on the practice cases, 17% answered a quiz, 96% used the atlas and 38% the ITV-T guide.
CONCLUSION: Expert evaluation with qualitative feedback improved contouring compliance. The JCI is not a reliable alternative to expert assessment. Moderate uptake of optional CME content limited evaluation. Crown
Copyright © 2020. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Delineation; EMBRACE-II; Education; Intensity modulated radiotherapy; Online; Quality assurance; Radiotherapy

Mesh:

Year:  2020        PMID: 32240907     DOI: 10.1016/j.radonc.2020.02.017

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

Review 1.  Metrics to evaluate the performance of auto-segmentation for radiation treatment planning: A critical review.

Authors:  Michael V Sherer; Diana Lin; Sharif Elguindi; Simon Duke; Li-Tee Tan; Jon Cacicedo; Max Dahele; Erin F Gillespie
Journal:  Radiother Oncol       Date:  2021-05-11       Impact factor: 6.901

2.  Clinical implementation of deep learning contour autosegmentation for prostate radiotherapy.

Authors:  Elaine Cha; Sharif Elguindi; Ifeanyirochukwu Onochie; Daniel Gorovets; Joseph O Deasy; Michael Zelefsky; Erin F Gillespie
Journal:  Radiother Oncol       Date:  2021-03-03       Impact factor: 6.901

3.  Comparison of survival, acute toxicities, and dose-volume parameters between intensity-modulated radiotherapy with or without internal target volume delineation method and three-dimensional conformal radiotherapy in cervical cancer patients: A retrospective and propensity score-matched analysis.

Authors:  Yu-Qin Liang; Sen-Quan Feng; Wen-Jia Xie; Qiong-Zhi Jiang; Yan-Fen Yang; Ren Luo; Elizabeth A Kidd; Tian-Tian Zhai; Liang-Xi Xie
Journal:  Cancer Med       Date:  2021-11-24       Impact factor: 4.452

4.  Impact of transitioning to an online course - A report from the ESTRO gyn teaching course.

Authors:  L T Tan; K Tanderup; A Nappa; P Petric; I M Jürgenliemk-Schulz; M Serban; J V Swamidas; M Palmu; S L Duke; U Mahantshetty; N Nesvacil; R C Pötter; R A Nout
Journal:  Clin Transl Radiat Oncol       Date:  2021-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.